Metabolic myopathies discovered during investigations of statin myopathy

Canadian Journal of Neurological Sciences

Volumn 35, Issue 1, 2008, Pages 94-97

  Baker, Steven K ^a   Vladutiu, Georgirene D ^a   Peltier, Wendy L ^b,c   Isackson, Paul J ^a   Tarnopolsky, Mark A ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY AT BUFFALO   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; BONE DISEASE; CASE REPORT; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROMYOGRAM; ELECTRON MICROSCOPY; ELECTROPHYSIOLOGY; ERGOMETRY; FATIGUE; GENE MUTATION; GENETIC ANALYSIS; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; ISOPRENYLATION; LABORATORY TEST; MALE; METABOLIC DISORDER; MUSCLE CRAMP; MYALGIA; MYOPATHY; NEEDLE BIOPSY; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; SKELETAL MYOTOXICITY; TRANSAMINITIS;

EID: 42049114223     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100007630     Document Type: Article

References (41)

1. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000; 22:441-57.
2. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000; 101:207-13.
3. Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC. Quantitation of prenylcysteines by a selective cleavage reaction. Proc Natl Acad Sci U S A. 1991; 88:9668-70.
4. Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006; 34:153-62.
5. Frudakis TN, Thomas MJ, Ginjupalli SN, Handelin B, Gabriel R, Gomez HJ. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics. 2007; 17:695-707.
6. Takeda M, Noshiro R, Onozato ML, Tojo A, Hasannejad H, Huang XL, et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur J Pharmacol. 2004; 483:133-8.
7. Oh J, Ban MR, Miskie BA, Pollex RL, Hegele RA. Genetic determinants of statin intolerance. Lipids Health Dis. 2007; 6:7.
8. Ruano G, Thompson PD, Windemuth A, Seip RL, Dande A, Sorokin A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007; 36:329-35.
9. Sirvent P, Mercier J, Vassort G, Lacampagne A. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun. 2005; 329:1067-75.
10. Kang L, Fang Q, Hu SJ. Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy. Arch Pharm Res. 2007; 30:596-602.
11. Velho JA, Okanobo H, Degasperi GR, Matsumoto MY, Alberici LC, Cosso RG, et al. Statins induce calcium-dependent mitochondrial permeability transition. Toxicology. 2006; 219:124-32.
12. Matzno S, Yasuda S, Juman S, Yamamoto Y, Nagareya-Ishida N, Tazuya-Murayama K, et al. Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol. 2005; 57:1475-84.
13. Sakamoto K, Honda T, Yokoya S, Waguri S, Kimura J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers. FASEB J. 2007; 21(14):4087-94.
14. Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001; 24:258-72.
15. Chariot P, Abadia R, Agnus D, Danan C, Charpentier C, Gherardi RK. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med. 1993; 94:109-10.
16. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS Syndrome. A case report. Eur Neurol. 2007; 57:232-5.
17. Goli AK, Goli SA, Byrd RP, Jr., Roy TM. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther. 2002; 72:461-4.
18. Perez-Calvo J, Civeira-Murillo F, Cabello A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. Qjm. 2005; 98:461-2.
19. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005; 102:8132-7.
20. Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet. 1989; 2:1097-8.
21. Haller RG. Treatment of McArdle disease. Arch Neurol. 2000; 57:923-4.
22. Tsao CY, Mendell JR. Combined partial deficiencies of carnitine palmitoyltransferase II and mitochondrial complex I presenting as increased serum creatine kinase level. J Child Neurol. 2002; 17:304-6.
23. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJ. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr. 1997; 156:562-4.
24. Delgado-Lopez F, Bautista-Lorite J, Villamil-Fernandez F. Worsening for using statin in carnitine palmityol transferase deficiency myopathy. Rev Neurol. 2004; 38:1095.
25. Arduini A, Peschechera A, Giannessi F, Carminati P. Improvement of statin-associated myotoxicity by L-carnitine. J Thromb Haemost. 2004; 2:2270-1.
26. Bhuiyan J, Seccombe DW. The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids. 1996; 31:867-70.
27. Kaufmann P, Torok M, Zahno A, Waldhauser KM, Brecht K, Krahenbuhl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci. 2006; 63(19-20):2415-25.
28. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res. 2007; 100:1442-51.
29. Scatena R, Bottom P, Martorana GE, Vincenzoni F, Botta G, Pastore P, et al. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology. Eur J Pharmacol. 2007; 567:50-8.
30. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 137:581-5.
31. Krivosic-Horber R, Depret T, Wagner JM, Maurage CA. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol. 2004; 21:572-4.
32. Guis S, Bendahan D, Kozak-Ribbens G, Figarella-Branger D, Mattel JP, Pellissier JF, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum. 2003; 49:237-8.
33. Livingstone C, Al Riyami S, Wilkins P, Ferns GA. McArdle's disease diagnosed following statin-induced myositis. Ann Clin Biochem. 2004; 41:338-40.
34. Tsivgoulis G, Spengos K, Karandreas N, Panas M, Kladi A, Manta P. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med. 2006; 166:1519-24.
35. Voermans NC, Lammens M, Wevers RA, Hermus AR, van Engelen BG. Statin-disclosed acid maltase deficiency. J Intern Med. 2005; 258:196-7.
36. Takagi A, Shiio Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku. 2004; 44:25-7.
37. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, Toribio E. Severe polymyositis with simvastatin use. Rev Neurol. 2003; 37:934-6.
38. Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001; 110:670-1.
39. Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004; 30:803-7.
40. Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002; 360:717.
41. Baker SK, Tarnopolsky MA. Sporadic rippling muscle disease unmasked by simvastatin. Muscle Nerve. 2006; 34:478-81.